Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Перспективы персонализации применения новых оральных антикоагулянтов у пациентов с фибрилляцией предсердий на основе оценки фармакокинетики
Перспективы персонализации применения новых оральных антикоагулянтов у пациентов с фибрилляцией предсердий на основе оценки фармакокинетики
Крюков А.В., Сычев Д.А., Савельева М.И., Рябова А.В., Ильина Е.С., Юровский А.Ю. Перспективы персонализации применения новых оральных антикоагулянтов у пациентов с фибрилляцией предсердий на основе оценки фармакокинетики. Consilium Medicum. 2015; 1: 41–43. DOI: 10.26442/2075-1753_2015.1.41-43
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Статья посвящена актуальной проблеме применения новых оральных антикоагулянтов (НОАК) у пациентов с фибрилляцией предсердий для вторичной профилактики инсульта. Терапевтический лекарственный мониторинг рассматривается как перспективный инструмент персонализации антикоагулянтной терапии, позволяющий предотвратить развитие осложнений, связанных с приемом НОАК.
Ключевые слова: фибрилляция предсердий, вторичная профилактика ишемического инсульта, новые оральные антикоагулянты, терапевтический лекарственный мониторинг.
Ключевые слова: фибрилляция предсердий, вторичная профилактика ишемического инсульта, новые оральные антикоагулянты, терапевтический лекарственный мониторинг.
________________________________________________
The article is devoted to the actual problem of non-vitamin K anticoagulants application (NOAC) for secondary stroke prevention in patients with atrial fibrillation. Therapeutic drug monitoring is considered a promising tool for personalized anticoagulation that allows to prevent the development of complications associated with NOAC administration.
Key words: atrial fibrillation, secondary prevention of ischemic stroke, non-vitamin K anticoagulants, therapeutic drug monitoring.
Key words: atrial fibrillation, secondary prevention of ischemic stroke, non-vitamin K anticoagulants, therapeutic drug monitoring.
Полный текст
Список литературы
1. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001; 86: 516–21.
2. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed a trial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370–5.
3. Miyasaka Y, Barnes ME, Gersh BJ et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119–25.
4. Heeringa J, Van der Kuip DA, Hofman A et al. Prevalence, incidence and life time risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949–53.
5. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009; 104: 1534–9.
6. Lloyd-Jones DM, Wang TJ, Leip EP et al. Life time risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110: 1042–6.
7. Wolf PA, Abbott RD, Kannel WB. A trial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983–8.
8. Murtagh B, Smalling RW. Cardioembolic stroke. Curr Atherosclr Rep 2006; 8: 310–6.
9. MacDougall NJJ, Amarasinghe S, Muir KW. Secondary prevention of stroke. Expert Rev Neurother 2009; 7: 1103–15.
10. Arboix A, García-Eroles L, Massons J, Oliveres M. Predictive clinical factors of in-hospital mortality in 231 consecutive patients with cardioembolic cerebral infarction. Cerebrovasc Dis 1998; 8: 8–13.
11. Arboix A, Alió J. Cardioembolic Stroke: Clinical Features, Specific Cardiac Disorders and Prognosis. Curr Cardiol Rev 2010; 6: 150–61.
12. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non valvular atrial fibrillation. Ann Intern Med 2007; 146: 857–67.
13. Atrial Fibrillation Investigators. Atrial Fibrillation, Aspirin, Anticoagulation Study; Boston Area Anticoagulation Trial for Atrial Fibrillation Study; Canadian Atrial Fibrillation Anticoagulation Study; Stroke Prevention in Atrial Fibrillation Study; Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Study. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation (published correction appears in Arch Intern Med 1994; 154: 2254). Arch Intern Med 1994; 154: 1449–57.
14. Guidelines for the management of atrial fibrillation. ESC 2012.
15. Practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. EHRA 2013.
16. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА, АССХ 2012. / Diagnostika i lechenie fibrilliatsii predserdii. Rekomendatsii RKO, VNOA, ASSKh 2012. [in Russian]
17. Shibazaki K, Kimura K, Aoki J et al. Early initiation of new oral anticoagulants in acute stroke and TIA patients with nonvalvular atrial fibrillation. J Neurol Sci 2013; 331 (1–2): 90–3.
18. Doll DN, Barr TL, Simpkins JW. Cytokines: their role in stroke and potential use as biomarkers and therapeutic targets. Aging Disease 2014; 5 (5): 294–306.
19. House RV, Descotes J. Cytokines in human health immunotoxicology, pathology, and therapeutic applications. 2007.
20. Cohen D. Dabigatran: how the drug company withheld important analyses. 2014.
21. Samama MM, Guinet C, Le Flem L. Do new oral anticoagulants require laboratory monitoring? The clinician point of view. Thromb Res 2012; 130 (Suppl. 1): s88–9.
22. Mani H, Herth N, Kasper A. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant. Ther Drug Monit 2014; 36 (5): 624–31.
23. Delavenne X, Moracchini J, Laporte S et al. UPLC MS/MS assay for routine quantification of dabigatran – a direct thrombin inhibitor – in human plasma. J Pharm Biomed Anal 2012; 58: 152–6.
24. Sobieraj-Teague M, O'Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation. Semin Thromb Hemost 2009; 35 (5): 515–24.
2. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed a trial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370–5.
3. Miyasaka Y, Barnes ME, Gersh BJ et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119–25.
4. Heeringa J, Van der Kuip DA, Hofman A et al. Prevalence, incidence and life time risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949–53.
5. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009; 104: 1534–9.
6. Lloyd-Jones DM, Wang TJ, Leip EP et al. Life time risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110: 1042–6.
7. Wolf PA, Abbott RD, Kannel WB. A trial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983–8.
8. Murtagh B, Smalling RW. Cardioembolic stroke. Curr Atherosclr Rep 2006; 8: 310–6.
9. MacDougall NJJ, Amarasinghe S, Muir KW. Secondary prevention of stroke. Expert Rev Neurother 2009; 7: 1103–15.
10. Arboix A, García-Eroles L, Massons J, Oliveres M. Predictive clinical factors of in-hospital mortality in 231 consecutive patients with cardioembolic cerebral infarction. Cerebrovasc Dis 1998; 8: 8–13.
11. Arboix A, Alió J. Cardioembolic Stroke: Clinical Features, Specific Cardiac Disorders and Prognosis. Curr Cardiol Rev 2010; 6: 150–61.
12. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non valvular atrial fibrillation. Ann Intern Med 2007; 146: 857–67.
13. Atrial Fibrillation Investigators. Atrial Fibrillation, Aspirin, Anticoagulation Study; Boston Area Anticoagulation Trial for Atrial Fibrillation Study; Canadian Atrial Fibrillation Anticoagulation Study; Stroke Prevention in Atrial Fibrillation Study; Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Study. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation (published correction appears in Arch Intern Med 1994; 154: 2254). Arch Intern Med 1994; 154: 1449–57.
14. Guidelines for the management of atrial fibrillation. ESC 2012.
15. Practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. EHRA 2013.
16. Diagnostika i lechenie fibrilliatsii predserdii. Rekomendatsii RKO, VNOA, ASSKh 2012. [in Russian]
17. Shibazaki K, Kimura K, Aoki J et al. Early initiation of new oral anticoagulants in acute stroke and TIA patients with nonvalvular atrial fibrillation. J Neurol Sci 2013; 331 (1–2): 90–3.
18. Doll DN, Barr TL, Simpkins JW. Cytokines: their role in stroke and potential use as biomarkers and therapeutic targets. Aging Disease 2014; 5 (5): 294–306.
19. House RV, Descotes J. Cytokines in human health immunotoxicology, pathology, and therapeutic applications. 2007.
20. Cohen D. Dabigatran: how the drug company withheld important analyses. 2014.
21. Samama MM, Guinet C, Le Flem L. Do new oral anticoagulants require laboratory monitoring? The clinician point of view. Thromb Res 2012; 130 (Suppl. 1): s88–9.
22. Mani H, Herth N, Kasper A. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant. Ther Drug Monit 2014; 36 (5): 624–31.
23. Delavenne X, Moracchini J, Laporte S et al. UPLC MS/MS assay for routine quantification of dabigatran – a direct thrombin inhibitor – in human plasma. J Pharm Biomed Anal 2012; 58: 152–6.
24. Sobieraj-Teague M, O'Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation. Semin Thromb Hemost 2009; 35 (5): 515–24.
2. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed a trial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370–5.
3. Miyasaka Y, Barnes ME, Gersh BJ et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119–25.
4. Heeringa J, Van der Kuip DA, Hofman A et al. Prevalence, incidence and life time risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949–53.
5. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009; 104: 1534–9.
6. Lloyd-Jones DM, Wang TJ, Leip EP et al. Life time risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110: 1042–6.
7. Wolf PA, Abbott RD, Kannel WB. A trial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983–8.
8. Murtagh B, Smalling RW. Cardioembolic stroke. Curr Atherosclr Rep 2006; 8: 310–6.
9. MacDougall NJJ, Amarasinghe S, Muir KW. Secondary prevention of stroke. Expert Rev Neurother 2009; 7: 1103–15.
10. Arboix A, García-Eroles L, Massons J, Oliveres M. Predictive clinical factors of in-hospital mortality in 231 consecutive patients with cardioembolic cerebral infarction. Cerebrovasc Dis 1998; 8: 8–13.
11. Arboix A, Alió J. Cardioembolic Stroke: Clinical Features, Specific Cardiac Disorders and Prognosis. Curr Cardiol Rev 2010; 6: 150–61.
12. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non valvular atrial fibrillation. Ann Intern Med 2007; 146: 857–67.
13. Atrial Fibrillation Investigators. Atrial Fibrillation, Aspirin, Anticoagulation Study; Boston Area Anticoagulation Trial for Atrial Fibrillation Study; Canadian Atrial Fibrillation Anticoagulation Study; Stroke Prevention in Atrial Fibrillation Study; Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Study. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation (published correction appears in Arch Intern Med 1994; 154: 2254). Arch Intern Med 1994; 154: 1449–57.
14. Guidelines for the management of atrial fibrillation. ESC 2012.
15. Practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. EHRA 2013.
16. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА, АССХ 2012. / Diagnostika i lechenie fibrilliatsii predserdii. Rekomendatsii RKO, VNOA, ASSKh 2012. [in Russian]
17. Shibazaki K, Kimura K, Aoki J et al. Early initiation of new oral anticoagulants in acute stroke and TIA patients with nonvalvular atrial fibrillation. J Neurol Sci 2013; 331 (1–2): 90–3.
18. Doll DN, Barr TL, Simpkins JW. Cytokines: their role in stroke and potential use as biomarkers and therapeutic targets. Aging Disease 2014; 5 (5): 294–306.
19. House RV, Descotes J. Cytokines in human health immunotoxicology, pathology, and therapeutic applications. 2007.
20. Cohen D. Dabigatran: how the drug company withheld important analyses. 2014.
21. Samama MM, Guinet C, Le Flem L. Do new oral anticoagulants require laboratory monitoring? The clinician point of view. Thromb Res 2012; 130 (Suppl. 1): s88–9.
22. Mani H, Herth N, Kasper A. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant. Ther Drug Monit 2014; 36 (5): 624–31.
23. Delavenne X, Moracchini J, Laporte S et al. UPLC MS/MS assay for routine quantification of dabigatran – a direct thrombin inhibitor – in human plasma. J Pharm Biomed Anal 2012; 58: 152–6.
24. Sobieraj-Teague M, O'Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation. Semin Thromb Hemost 2009; 35 (5): 515–24.
________________________________________________
2. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed a trial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370–5.
3. Miyasaka Y, Barnes ME, Gersh BJ et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119–25.
4. Heeringa J, Van der Kuip DA, Hofman A et al. Prevalence, incidence and life time risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949–53.
5. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009; 104: 1534–9.
6. Lloyd-Jones DM, Wang TJ, Leip EP et al. Life time risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110: 1042–6.
7. Wolf PA, Abbott RD, Kannel WB. A trial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983–8.
8. Murtagh B, Smalling RW. Cardioembolic stroke. Curr Atherosclr Rep 2006; 8: 310–6.
9. MacDougall NJJ, Amarasinghe S, Muir KW. Secondary prevention of stroke. Expert Rev Neurother 2009; 7: 1103–15.
10. Arboix A, García-Eroles L, Massons J, Oliveres M. Predictive clinical factors of in-hospital mortality in 231 consecutive patients with cardioembolic cerebral infarction. Cerebrovasc Dis 1998; 8: 8–13.
11. Arboix A, Alió J. Cardioembolic Stroke: Clinical Features, Specific Cardiac Disorders and Prognosis. Curr Cardiol Rev 2010; 6: 150–61.
12. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non valvular atrial fibrillation. Ann Intern Med 2007; 146: 857–67.
13. Atrial Fibrillation Investigators. Atrial Fibrillation, Aspirin, Anticoagulation Study; Boston Area Anticoagulation Trial for Atrial Fibrillation Study; Canadian Atrial Fibrillation Anticoagulation Study; Stroke Prevention in Atrial Fibrillation Study; Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Study. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation (published correction appears in Arch Intern Med 1994; 154: 2254). Arch Intern Med 1994; 154: 1449–57.
14. Guidelines for the management of atrial fibrillation. ESC 2012.
15. Practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. EHRA 2013.
16. Diagnostika i lechenie fibrilliatsii predserdii. Rekomendatsii RKO, VNOA, ASSKh 2012. [in Russian]
17. Shibazaki K, Kimura K, Aoki J et al. Early initiation of new oral anticoagulants in acute stroke and TIA patients with nonvalvular atrial fibrillation. J Neurol Sci 2013; 331 (1–2): 90–3.
18. Doll DN, Barr TL, Simpkins JW. Cytokines: their role in stroke and potential use as biomarkers and therapeutic targets. Aging Disease 2014; 5 (5): 294–306.
19. House RV, Descotes J. Cytokines in human health immunotoxicology, pathology, and therapeutic applications. 2007.
20. Cohen D. Dabigatran: how the drug company withheld important analyses. 2014.
21. Samama MM, Guinet C, Le Flem L. Do new oral anticoagulants require laboratory monitoring? The clinician point of view. Thromb Res 2012; 130 (Suppl. 1): s88–9.
22. Mani H, Herth N, Kasper A. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant. Ther Drug Monit 2014; 36 (5): 624–31.
23. Delavenne X, Moracchini J, Laporte S et al. UPLC MS/MS assay for routine quantification of dabigatran – a direct thrombin inhibitor – in human plasma. J Pharm Biomed Anal 2012; 58: 152–6.
24. Sobieraj-Teague M, O'Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation. Semin Thromb Hemost 2009; 35 (5): 515–24.
Авторы
А.В.Крюков, Д.А.Сычев*, М.И.Савельева, А.В.Рябова, Е.С.Ильина, А.Ю.Юровский
ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1
*dimasychev@mail.ru
ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1
*dimasychev@mail.ru
________________________________________________
A.V.Kryukov, D.A.Sychev*, M.I.Saveleva, A.V.Ryabova, E.S.Ilina, A.Yu.Yurovsky
Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
*dimasychev@mail.ru
Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
*dimasychev@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.